Although many pivotal HF RCTs excluded patients with severe CKD, it was shown that the group of patients with the highest prevalence of CKD had the most benefit from ACE inhibitor/ARB treatment across the EF spectrum [23, 26, 28, 30]. This evidence concerns the gene ACE and chronic kidney disease.